Citadel Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-92,200
| Closed | -$9.4M | – | 15471 |
|
|
2023
Q2 | $9.4M | Sell |
92,200
-63,300
| -41% | -$5.99M | ﹤0.01% | 2760 |
|
|
2023
Q1 | $14.1M | Buy |
155,500
+600
| +0.4% | +$35.2K | ﹤0.01% | 2346 |
|
|
2022
Q4 | $5.88M | Buy |
154,900
+29,900
| +24% | +$1.03M | ﹤0.01% | 3593 |
|
|
2022
Q3 | $3.14M | Buy |
125,000
+41,500
| +50% | +$1.15M | ﹤0.01% | 4724 |
|
|
2022
Q2 | $2.54M | Sell |
83,500
-128,400
| -61% | -$3.83M | ﹤0.01% | 5069 |
|
|
2022
Q1 | $6.94M | Buy |
211,900
+123,500
| +140% | +$3.66M | ﹤0.01% | 3564 |
|
|
2021
Q4 | $2.33M | Buy |
88,400
+5,500
| +7% | +$426K | ﹤0.01% | 5888 |
|
|
2021
Q3 | $8.34M | Buy |
82,900
+32,600
| +65% | +$3.82M | ﹤0.01% | 3385 |
|
|
2021
Q2 | $7.12M | Sell |
50,300
-18,100
| -26% | -$2.04M | ﹤0.01% | 3710 |
|
|
2021
Q1 | $6.82M | Buy |
68,400
+27,700
| +68% | +$3.23M | ﹤0.01% | 3640 |
|
|
2020
Q4 | $5.03M | Sell |
40,700
-8,400
| -17% | -$1.1M | ﹤0.01% | 3676 |
|
|
2020
Q3 | $4.78M | Buy |
49,100
+24,600
| +100% | +$3.07M | ﹤0.01% | 3229 |
|
|
2020
Q2 | $3.82M | Sell |
24,500
-12,300
| -33% | -$1.87M | ﹤0.01% | 3469 |
|
|
2020
Q1 | $5.31M | Buy |
36,800
+17,100
| +87% | +$3.3M | ﹤0.01% | 2622 |
|
|
2019
Q4 | $4.03M | Buy |
19,700
+9,200
| +88% | +$1.68M | ﹤0.01% | 3356 |
|
|
2019
Q3 | $843K | Sell |
10,500
-20,600
| -66% | -$1.75M | ﹤0.01% | 5889 |
|
|
2019
Q2 | $2.93M | Buy |
31,100
+7,400
| +31% | +$639K | ﹤0.01% | 3891 |
|
|
2019
Q1 | $2.03M | Buy |
23,700
+4,700
| +25% | +$390K | ﹤0.01% | 4438 |
|
|
2018
Q4 | $1.07M | Buy |
19,000
+4,600
| +32% | +$281K | ﹤0.01% | 5204 |
|
|
2018
Q3 | $1.18M | Buy |
+14,400
| New | +$1.01M | ﹤0.01% | 5265 |
|
Other funds holding RETA
Citadel Advisors's RETA Position: Q3 2023 in Review
Citadel Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 571,529 shares — an estimated $58.3M sold.
Citadel Advisors first reported a position in RETA in Q3 2017 and held it in 22 quarters. The position peaked at $58.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Citadel Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 571,529 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $58.3M.
- Citadel Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 22 quarters.
- Citadel Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $58.3M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.